Cemiplimab trade name

Cemiplimab (Cemiplimab) is a monoclonal antibody drug used to treat squamous cell skin cancer, with the trade name Libtayo. Cimepilimab belongs to a class of drugs that bind to programmed death receptor-1 (PD-1) and can block the PD-1/PD-L1 pathway. It can inhibit the PD-L1 protein on the surface of tumor cells from binding to the PD-1 receptor in the immune system, thereby activating the patient's own immune system to attack and destroy cancer cells. . Cimepilimab is approved for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma, non-small cell lung cancer, and cervical cancer. The most common side effects include fatigue, rash, diarrhea, musculoskeletal pain, and nausea.